1 2 3 4 5 6 7 8	LAW OFFICES OF RONALD A. MAR RONALD A. MARRON (SBN 175650) ron@consumersadvocates.com MICHAEL T. HOUCHIN (SBN 305541) mike@consumersadvocates.com LILACH HALPERIN (SBN 323202) lilach@consumersadvocates.com 651 Arroyo Drive San Diego, California 92103 Telephone: (619) 696-9006 Facsimile: (619) 564-6665 Attorneys for Plaintiffs and the Proposed	
10	UNITED STATES DISTRICT COURT	
11	CENTRAL DISTRICT OF CALIFORNIA	
12		
13		
14	FRANK CAPACI and CYNTHIA FORD on behalf of themselves, all others	Case No.: 2:19-cv-03440-FMO-FFM
15	similarly situated, and the general public,	SECOND AMENDED CLASS
16	Plaintiffs,	ACTION COMPLAINT
17	Tiamuits,	DEMAND FOR JURY TRIAL
18	v.	
19		
20	SPORTS RESEARCH, INC., a California	
21	Corporation.	
22	Defendant.	
23		
24		
25		
26		
27		
28		

th u: R

Plaintiffs Frank Capaci and Cynthia Ford ("Plaintiffs"), on behalf of themselves, all others similarly situated, and the general public, by and through their undersigned counsel, hereby sue Defendant Sports Research Corporation ("Sports Research" or "Defendant") and, upon information and belief and investigation of counsel, allege as follows:

#### I. <u>INTRODUCTION</u>

- 1. Defendant Sports Research Corporation markets "Sports Research Garcinia Cambogia" ("Garcinia Cambogia" or the "Product"), a dietary supplement that Defendant falsely claims is an effective aid in "weight management" and "appetite control", despite the fact that the Product's only purportedly active ingredients, Hydroxycitric Acid ("HCA") and extra virgin organic coconut oil, are scientifically proven to be incapable of providing such weight-loss benefits.
- 2. Plaintiffs read and relied upon Defendant's claims when purchasing the Product and were damaged as a result.
- 3. Plaintiffs bring this action challenging Defendant's misleading weightloss claims relating to the Product on behalf of themselves and all other similarly situated consumers in the United States, alleging violations of the California Consumer Legal Remedies Act, Cal. Civ. Code§§ 1750 et seq. ("CLRA"), Unfair Competition Law, Cal. Bus. & Prof. Code§§ 17200 et seq. ("UCL"), and False Advertising Law, id. §§ 17500 et seq. ("FAL"). Plaintiffs further allege that Defendant breached express and implied warranties under state law. In addition, Plaintiffs further allege that Defendant has violated New Jersey's Consumer Fraud Act, N.J.S.A. ¶ 56:8-1, et seq. and New Jersey's Truth-In-Consumer Contract, Warranty, and Notice Act, N.J.S.A. ¶¶ 56:12-14 TO 56:12-18 ("TCCWNA").
- 4. Plaintiffs seek an order compelling Defendant to (a) cease marketing the Product using the misleading and unlawful tactics complained of herein, (b) destroy all misleading, deceptive, and unlawful materials, (c) conduct a corrective advertising campaign, (d) restore the amounts by which it has been unjustly

enriched, and (e) pay restitution damages and punitive damages, as allowed by law

#### II. <u>JURISDICTION AND VENUE</u>

- 5. This Court has original jurisdiction under 28 U.S.C. §1332(d)(2) (The Class Action Fairness Act) because the matter in controversy exceeds the sum or value of \$5,000,000 exclusive of interest and costs and because more than two-thirds of the members of the Class reside in states other than the state of which Defendant is a citizen.
- 6. The court has personal jurisdiction over Defendant because it is a California corporation with its principal place of business in California. Defendant has purposely availed itself of the benefits and privileges of conducting business activities within California, and consented to personal jurisdiction by registering to do business in California.
- 7. Venue is proper in this Court pursuant to 28 U.S.C. §1391 because Sports Research is authorized to conduct business in this District and its principal place of business is located in this District. Defendant has intentionally availed itself of the laws and markets of this District through the promotion, marketing, distribution, and sale of the Product in this District, and is subject to personal jurisdiction in this District.

#### III. PARTIES

- 8. Defendant Sports Research Corporation is a California corporation with its principal place of business in San Pedro, California. Defendant is registered to do business in California as entity number C1022324. Defendant develops, manufactures, promotes, markets, distributes, and/or sells the Product across the United States, including to hundreds of consumers in California and New Jersey.
- 9. Plaintiff Frank Capaci ("Plaintiff Capaci") is a resident of New Jersey and purchased the Product for personal and household use and not for resale at a GNC store located on 3036 State Route 35 in Hazlet, New Jersey and at a GNC store located on 2101 Highway 35 in Holmdel, New Jersey during the Class Period

defined herein. Plaintiff Capaci paid approximately \$25.00 for the Products that he purchased. Plaintiff Capaci saw the misrepresentations made on the Product label prior to and at the time of purchase and understood them as representations and warranties that the Product was safe and effective for appetite control and weight management as advertised. Mr. Capaci relied on the representations made on the Product's label in deciding to purchase the Product. These representations and warranties were part of his basis of the bargain, in that he would not have purchased the Product had he known the representations were false. Plaintiff Capaci would consider purchasing the Product again if the advertising statements made on the Product labels were, in fact, truthful and represented in a manner as not to deceive consumers.

10. Plaintiff Cynthia Ford ("Plaintiff Ford") is a resident of California and purchased the Product for personal and household use and not for resale at a Vitamin Shoppe store located on 5600 East 7th Street, Long Beach, California around January 2018. Plaintiff Ford paid approximately \$20.00 to \$25.00 for the Product that she purchased. Plaintiff Ford saw the misrepresentations made on the Product label prior to and at the time of purchase and understood them as representations and warranties that the Product was safe and effective for appetite control and weight management as advertised. Ms. Ford relied on the representations made on the Product's label in deciding to purchase the Product. These representations and warranties were part of her basis of the bargain, in that she would not have purchased the Product had she known the representations were false. Plaintiff Ford would consider purchasing the Product again if the advertising statements made on the Product labels were, in fact, truthful and represented in a manner as not to deceive consumers.

#### IV. NATURE OF THE ACTION

11. On June 17, 2014, the United States Senate Subcommittee on Consumer Protection, Product Safety, and Insurance held a hearing titled *Protecting* 

- Consumers from False and Deceptive Advertising of Weight-Loss Supplement Products.<sup>1</sup> In her opening statement, committee chairwoman— Former Senator Claire McCaskill— stated that "With so many Americans desperate for anything that might make it easier to lose weight, it's no wonder scam artists and fraudsters have turned to the \$60-billion weight-loss market to make a quick buck."
- 12. False advertising of weight-loss products is truly an epidemic. Government regulators are overwhelmed because "One out of ten fraud claims submitted to the FTC are, in fact, for weight-loss products." Indeed, Senator McCaskill stated that "the problem is much larger than any enforcement agency could possibly tackle on its own. Private stakeholders, companies that sell weight-loss products, media outlets, and other advertising platforms, *as well as consumer watchdogs*, must all do their part to help address this problem."

#### A. Defendant's Sale and Marketing of the Product

- 13. Plaintiffs and the proposed Class members are all purchasers of Sports Research Corporation's brand weight-loss supplement "Garcinia Cambogia" product (the "Product") that contains Garcinia Cambogia extract, standardized to Total Hydroxycitric Acid (HCA).
- 14. Defendant has distributed, marketed, and sold the Product on a nationwide basis, including California and New Jersey, for at least the past several years.
- 15. The Product is sold online and at popular supplement retailers like GNC and Vitamin Shoppe and sells at a retail price of approximately \$20.00 \$25.00.
- 16. The Product comes in "liquid softgel capsules" form and are sold in various quantities, including bottles of 90 and 180 liquid softgel capsules.

<sup>&</sup>lt;sup>1</sup> Official transcript of *Protecting Consumers From False and Deceptive Advertising of Weight-Loss Products, Before the Subcommittee on Consumer Protection, Product Safety and Insurance of the United States Senate,* 113TH CONG. 2ND. SESS. (June 14, 2016), *available at* https://www.gpo.gov/fdsys/pkg/CHRG-113shrg92998/pdf/CHRG-113shrg92998.pdf.

- 17. Defendant markets and advertises the Product as an effective weightloss supplement through claims placed directly on the Product's bottle despite that it provides no such benefits.
- 18. For purposes of this section, each statement that appears in quotation marks ("") below create affirmative representations about the Product and also create express and implied warranties that were relied on by Plaintiffs and the Class members in deciding to purchase the Product.
- 19. These statements will from now on be referred to in this First Amended Complaint as the "Express Warranties" and they also form the basis of Plaintiffs' consumer fraud and misrepresentation causes of action.
  - 20. Below are true and correct copies of the Product's front and side labels:

26 || // 27 || //

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

28

//

//

//

//

//

//

//

//

//


//

//

//







6

9

14 15

16

17 18

19 20

22

21

24 25

23

26

27

28

- 21. The front label of the Product states that it is "garcinia cambogia" and is "made with 65% HCA & coconut oil."
- 22. The left-side label of the Product states "Sports Research Garcinia Cambogia with Coconut Oil is standardized to 65% Hydroxycitric Acid (HCA) – the active component in Garcinia Cambogia studied for its potential to suppress appetite.\*"
- 23. Following this sentence, Defendant promises that "Along with diet and exercise, Garcinia Cambogia is a great way to support your overall weight management plan."
- Under its "weight management" claim, Defendant prominently labels 24. the Product with the yellow-highlighted phrase "Supports Appetite Control\*".
- 25. The above-quoted statements are false, misleading, deceptive, and unlawful for the reasons explained herein. Moreover, the above-quoted statements create express or implied warranties and Defendant has breached said warranties for the reasons described herein.
- 26. Defendant's misleading "Appetite Control" and "Weight Management" claims convey that the Product is capable of helping consumers lose weight and will actually help consumers lose weight, by suppressing appetite. However, these claims, taken individually and especially in context of the label as a whole, are misleading because the Product's only "active" ingredients are incapable of providing any weight-loss benefits.
- 27. In short, the claims on the packaging of the Product convey the concrete overall message that the Product by means of its HCA, can effectively help consumers lose weight. Defendant intended consumers to rely upon this message, which is false and misleading for the reasons stated herein.

#### **B**. The Deceptive Labeling of the Product

28. randomized, controlled scientific studies Numerous placebo demonstrate that Garcinia Cambogia extract and/or HCA does not provide weightloss or appetite control benefits in humans. In fact, the only reliable scientific evidence demonstrates it is no more effective as a weight-management aid than a placebo.

- 29. A significant *Garcinia*/HCA weight loss study was published in 1998 by a group of researchers at Columbia University's Obesity Research Center that was led by Dr. Heymsfield and published in the *Journal of the American Medical Association*.<sup>2</sup> This study was, and remains, one of the longest duration (12 weeks) and largest (135 subjects divided equally into placebo and control groups) randomized double-blind clinical trials of *Garcinia cambogia*.
- 30. The study found that a *Garcinia* extract failed to produce a significant loss of weight and fat mass beyond that observed with placebo.<sup>3</sup>
- 31. *The Hemsfield* study has stood the test of time. In 2011, it was one of only 12 clinical trials deemed worthy of inclusion in a landmark meta-analyses of supplements like *Garcinia cambogia* and is assigned the highest Jadad score<sup>4</sup> of all included studies.<sup>5,6</sup>

<sup>&</sup>lt;sup>2</sup> S.B. Heymsfield, *et al.*, "Garcinia Cambogia (Hydroxycitric Acid) As a Potential Antiobesity Agent: A Randomized Controlled Trial," *J. Amer. Med. Assoc.* 280(18):1596-600 (1998). *Full text available at* http://jama.jamanetwork.com/article.aspx?articleid=188147. (Accessed October 14, 2015).

 $<sup>^3</sup>$  In fact, the data suggests that the placebo group, on average, consistently lost <u>more</u> weight than the *Garcinia* treatment group across the entire time course of the study.

<sup>&</sup>lt;sup>4</sup> "Jadad score" is a benchmark measuring the likelihood of bias in clinical trials, with higher numbers indicating lower likelihoods of bias. For a meta-analysis, Jadad scoring is carried out by a panel of scientists who are themselves blinded as to the authorship of articles.

<sup>&</sup>lt;sup>5</sup> See Table 1 in I. Onakpoya, et al., "The Use of Garcinia Extract (Hydroxycitric Acid) as a Weight Loss Supplement: A Systematic Review and Meta-Analysis of Randomised Clinical Trials," J. OBESITY (2011), http://www.hindawi.com/journals/jobe/2011/509038/.

<sup>&</sup>lt;sup>6</sup> Heymsfield recently defended his results and stated that marketers of *Garcinia cambogia* are "weaving a story with obscure facts. Maybe each fragment has some validity, but if you wind it together it makes no sense at all." *See "The Claims Make this Supplement Tempting, But They're Untrue*," Consumer Reports (Aug. 10, 2015)

- 32. In 2004, Max Pittler and Edzard Ernst, complementary medicine researchers at the universities of Exeter and Plymouth, published a systematic review of prior meta-analyses<sup>7</sup> and clinical trials of a variety of over-the-counter weight loss aids in *The American Journal of Clinical Nutrition*. The results indicated that none of the weight loss aids worked, including the *Garcinia cambogia* products reviewed. Moreover, adverse events were reported in the *Garcinia* trials reviewed. The report concluded that "none of the reviewed dietary supplements," which included Garcinia cambogia, "can be recommended for over-the-counter use."<sup>8</sup>
- 33. Since hydroxycitric acid reportedly promotes weight loss, in part, through suppression of hunger, a study was conducted to determine the effects of hydroxycitric acid on appetitive variables. The active treatment group did not exhibit better dietary compliance or significant correlations between appetitive variables and energy intake or weight change. This study does not support a satiety effect of hydroxycitric acid.<sup>9</sup>
- 34. A study was conducted to assess the effects of acute hydroxycitric acid supplementation on substrate metabolism at rest and during exercise in humans. Hydroxycitric acid, even when provided in large quantities, does not increase total fat oxidation in vivo in endurance-trained humans.<sup>10</sup>
  - 35. Meta-analyses of research on Garcinia cambogia and/or HCA have

<sup>&</sup>lt;sup>7</sup> A meta-analysis contrasts and combines results from different studies in an attempt to identify patterns among study results, sources of disagreement, and other relationships between the studies.

<sup>&</sup>lt;sup>8</sup> M.H. Pittler & E. Ernst, "Dietary Supplements for Body-Weight Reduction: A Systematic Review," AMER. J. OF CLIN. NUTR. (May 2004).

<sup>&</sup>lt;sup>9</sup> Mattes R, Bormann L. Effects of (-)-hydroxycitric acid on appetitive variables. *Physiol Behav* 2000, 71:87-94.

<sup>&</sup>lt;sup>10</sup> van Loon L, van Rooijen J, Niesen B, Verhagen H, Saris W, Wagenmakers A. Effects of acute (-)- hydroxycitrate supplementation on substrate metabolism at rest and during exercise in humans. Am J Clin Nutr 2000, 72:1445-50.

8

11 12

14

15

13

16 17

18

19 20

21 22

24 25

23

26

27 28

evaluated all known published credible human scientific studies. The meta-analyses uniformly conclude that HCA-containing supplements, such as the Product at issue, have little or no positive effect on weight loss in healthy individuals.

- 36. The results of more recent studies have been the same: "Garcinia cambogia extract did not show dietary efficacy."<sup>11</sup>
- 37. A 2008 study published in the Journal of Clinical Biochemistry and *Nutrition*, found that "hydroxycitric acid had no significant effect on the body component" and that "dietary efficacy was not indicated." *Id.* at 100.
- 38. That study, which employed a "double-blind, non-cross-matching test," found that "Garcinia cambogia extract did not show dietary efficacy." Id. at 90, 101.
- A 2011 study publish in the prominent Nutrition Journal found that 39. Garcinia Cambogia extract supplementation "failed to promote weight-loss or any clinically significant change in % body fat."<sup>12</sup>
- 40. The researchers noted that "the evidence for the effectiveness of natural food supplements to promote weight-loss and improve health is largely derived from animal studies. Therefore, it is essential randomized double-blind placebocontrolled trials (RCTs) are conducted to determine the effectiveness of natural food supplements to promote weight-loss." Id. at 94-95.
- 41. The randomized double-blind placebo-controlled trial found that "GCE supplementation [garcinia cambogia extract] was not effective in promoting weightloss in overweight individuals." *Id.* at 101.
- Further, "[i]n agreement with past studies the present study provided 42. no evidence that GCE supplementation [garcinia cambogia extract] can modify

<sup>&</sup>lt;sup>11</sup> Yoshikazu Yonei et. al, Effects on the Human Body of a Dietary Supplement Containing L-Camitine and Garcinia Cambogia Extract: A Study using Double-blind Tests, 42 J. Clin. Biochem. Nutr. 89, 101 (2008).

<sup>&</sup>lt;sup>12</sup> Kim et al., Does Glycine max leaves or Garcinia Cambogia promote weight-loss or lower plasma cholesterol in overweight individuals: a randomized control trial, 10 Nutr. J. 94, 94 (2011).

calorie intake in overweight individuals consuming their habitual diet." *Id.* at 102.

- 43. These studies, all of which were controlled human trials, affirmatively demonstrate that Garcinia Cambogia extract (HCA) does not and cannot aid weight management or appetite control.
- 44. Indeed, the Food and Drug Administration's (FDA) Office of Dietary Supplements concludes that based on research findings, that "Garcinia cambogia has little to no effect on weight loss."<sup>13</sup>
- 45. Coconut oil is also ineffective at promoting weight loss. According to the Mayo Clinic, "[t]here is no evidence that coconut oil will have a beneficial effect on weight loss if you simply add it to your diet."<sup>14</sup>
- C. The Labeling of the Product Violates California and Federal Statutes and Regulations
  - i. Any Violation of Federal Food Labeling Statutes or Regulations is a Violation of California Law
- 46. Pursuant to the California Sherman Food, Drug, and Cosmetic Law, Cal. Health & Safety Code§§ 109875 *et. seq.* (the "Sherman Law"), California has adopted the federal food and dietary supplement labeling requirements as its own. *See id.* § 110665 ("Any food is misbranded if its labeling does not conform with the requirements for nutrition labeling as set forth in Section 403(q) (21 U.S.C. Sec. 343(q)) of the federal act and the regulation adopted pursuant thereto."); *id.* § 110670 ("Any food is misbranded if its labeling does not conform with the requirements for nutrient content or health claims as set forth in Section 403(r) (21 U.S.C. Sec. 343(r)) of the federal act and the regulations adopted pursuant thereto.").

<sup>&</sup>lt;sup>13</sup> See Dietary Supplements for Weight Loss, available at https://ods.od.nih.gov/factsheets/WeightLoss-Consumer/

<sup>&</sup>lt;sup>14</sup> See Coconut oil for weight loss: Does it work?, Mayo Clinic, available at https://www.mayoclinic.org/healthy-lifestyle/weight-loss/in-depth/coconut-oil-and-weight-loss/art-20450177

10

11

12 13

14

15 16

17 18

19 20

21 22

23 24

25 26

- 47. For the purposes of labeling, "a dietary supplement shall be deemed to be a food." See 21 U.S.C. § 321(ff).
- 48. The Federal Food, Drug, and Cosmetic Act expressly authorizes state regulations, such as the Sherman Law, that are "identical to the requirement[s]" of the FDCA and federal regulations. See 21 U.S.C. § 343-1.
- Because the Sherman Law's requirements are identical to the 49. requirements of the Federal Food, Drug, and Cosmetic Act and FDA regulations, the Sherman law is explicitly authorized by the FDCA.
  - ii. The Product's False and Misleading Labeling Claims Render it Misbranded Under California and Federal Law
- 50. Defendant's deceptive statements described herein violate Cal. Health & Safety Code §§ 110390 and 110660, and 21 U.S.C. § 343(a), which deem a food or dietary supplement misbranded if its labeling is "false or misleading in any particular."
- Further, Defendant's labeling of the Product is misleading, and thus 51. misbranded, because "it fails to reveal facts that are material in light of other representations." 21 C.F.R. §1.21. For example, in light of the Product's weight-loss claims the labeling fails to reveal the fact that numerous randomized, controlled human trials demonstrate that Garcinia Cambogia is not effective or capable of aiding weight loss.
- 52. The Product is further misbranded because its labeling and packaging bear structure function claims even though the Product does not meet the requirements to make such claims.
- 53. Specifically, the statements "Weight Management Support" and "Appetite Control" are structure function claims.
- These claims violate 21 U.S.C. 343(r)(6) because the weight of 54. scientific evidence does not support these claims as being "truthful and not misleading" as required. See 21 U.S.C. 343(r)(6). To the contrary, scientific

evidence, as alleged herein, affirmatively demonstrates that the Product's purportedly "active" ingredients are incapable of providing any dietary benefits.

#### D. Plaintiffs' Purchases, Reliance, and Injury

- 55. During the class period, Plaintiff Frank Capaci purchased Sports Research Garcinia Cambogia in reliance on the Product's misleading dietary claims from GNC stores in New Jersey. The cost was approximately \$25 per bottle.
- 56. During the class period, Plaintiff Cynthia Ford purchased Sports Research Garcinia Cambogia in reliance on the Product's misleading dietary claims from a Vitamin Shoppe store in Long Beach, California. The cost of the Product was approximately \$20 to \$25.
- 57. When deciding to purchase the Product, Plaintiffs read and relied on the claims that "Garcinia Cambogia is a great way to support your overall weight management plan" and that the Product "Supports Appetite Control," which appears directly on the Product's label and packaging.
- 58. Based on these representations, Plaintiffs believed the Product was an effective dietary aid that would provide weight-loss benefits and would help them lose weight and help control their appetite.
- 59. When purchasing the Product, Plaintiffs were seeking a product that had the qualities described on the Product's label, namely, an effective supplement that aids in weight loss.
- 60. Plaintiffs read and relied upon Defendant's claims when purchasing the Product.
- 61. After using the Product, Plaintiffs did not experience the benefits promised by the Product labels.
- 62. The representations on the Product's label were and are false and misleading, and had the capacity, tendency, and likelihood to confuse or confound Plaintiffs and other consumers acting reasonably (including the putative Class) because, as described in detail herein, the Product cannot deliver the purported

benefits and is no more effective than a placebo.

63. Plaintiffs acted reasonably in relying on the challenged claims that Defendant intentionally placed on the Product's label and packaging with the intent to induce average consumers into purchasing it.

64. Mr. Capaci first discovered Defendant's unlawful acts described herein in October 2018, when he learned that the Defendant's Product violates the FDCA and its implementing regulations and that the labels were untrue and/or misleading.

7 8

65. Plaintiff Ford first discovered Defendant's unlawful acts described herein in June 2019, when she learned that the Product's labels were untrue and/or misleading and violate the FDCA and its implementing regulations.

66. Instead of receiving a product that had actual beneficial weight-loss properties, the Product that Plaintiffs and the Class received was one that does not and cannot deliver the claimed benefits.

67. Plaintiffs, in the exercise of reasonable diligence, could not have discovered earlier Defendant's unlawful acts described herein because the violations were known to Defendant, and not to them, throughout the Class Period defined herein.

68. The Product, which has the sole intended purpose as a dietary aid, is worthless since it is incapable of providing any such benefits.

69. The Product costs more than similar products without misleading labeling, and would have cost less absent the false and misleading statements.

70. Plaintiffs paid more for the Product, and would only have been willing to pay less, or unwilling to purchase it at all, absent the false and misleading labeling statements complained of herein.

71. For these reasons, the Product was worth less than what Plaintiffs paid for it.

72. Plaintiffs would not have purchased the Product if they knew it was misbranded pursuant to FDA regulations and could not be legally sold or held and

thus is legally worthless.

- 73. Plaintiffs would like to, and would consider purchasing the Product again when they can do so with the assurance that the Product's label, which indicates that the Product helps reduce belly fat and achieve weight loss, is truthful and consistent with the Product's active ingredients.
- 74. Plaintiffs will be unable to rely on the Product's advertising or labeling in the future, and so will not purchase the product again although they would like to.
- 75. Plaintiffs lost money as a result of Defendant's deceptive claims and practices in that they did not receive what they paid for when purchasing the Product.
- 76. Plaintiffs detrimentally altered their position and suffered damages in an amount equal to the amount they paid for the Product.
- 77. The senior officers and directors of Defendant allowed the Product to be sold with full knowledge or reckless disregard that the challenged claims are fraudulent, unlawful, and misleading.

#### V. <u>CLASS ACTION ALLEGATIONS</u>

78. Pursuant to Federal Rule of Civil Procedure 23, Plaintiffs seek certification of the following Classes (or alternative Classes or Subclasses), for the time period from when the Sports Research Garcinia Cambogia Product first entered into the stream of commerce until the present ("Class Period"), as defined as follows:

#### The Nationwide Class is defined as follows:

All U.S. citizens who purchased the Product in their respective state of citizenship for personal and household use and not for resale during the Class Period.

#### The California sub-class is defined as follows:

All California citizens who purchased the Product in California for personal and household use and not for resale during the Class Period.

#### The New Jersey sub-class is defined as follows:

All New Jersey citizens who purchased the Product in New Jersey for personal and household use and not for resale during the Class Period.

- 79. The Classes and Subclasses described in this complaint will jointly be referred to as the "Class" or the "Classes" unless otherwise stated, and the proposed members of the Classes and Subclasses will jointly be referred to as "Class Members."
- 80. Plaintiffs and the Class reserve their right to amend or modify the Class definitions with greater specificity or further division into subclasses or limitation to particular issues as discovery and the orders of this Court warrant.
- 81. Excluded from the Class are governmental entities, Defendant, any entity in which Defendant has a controlling interest, Defendant's employees, officers, directors, legal representatives, heirs, successors and wholly or partly owned subsidiaries or affiliated companies, including all parent companies, and their employees; and the judicial officers, their immediate family members and court staff assigned to this case.
- 82. The members in the proposed Class are so numerous that individual joinder of all members is impracticable. Due to the nature of the trade and commerce involved, however, Plaintiffs believe the total number of Class members is at least in the hundreds and members of the Classes are numerous. While the exact number and identities of the Class members are unknown at this time, such information can be ascertained through appropriate investigation and discovery. The disposition of the claims of the Class members in a single class action will provide substantial benefits to all parties and to the Court.
- 83. Pursuant to Rule 23(b)(2), Defendant has acted or refused to act on grounds generally applicable to the Classes, thereby making final injunctive relief or corresponding declaratory relief and damages as to the Product appropriate with

respect to the Classes as a whole. In particular, Defendant has failed to disclose the true nature of the Product being marketed as described herein.

- 84. There is a well-defined community of interest in the questions of law and fact involved, affecting the Plaintiffs and the Classes and these common questions of fact and law include, but are not limited to, the following:
  - a. Whether Defendant breached any express warranties made to Plaintiffs and the Class;
  - b. Whether Defendant breached any implied warranties made to Plaintiffs and the Class;
  - c. Whether Defendant engaged, and continues to engage, in unfair or deceptive acts and practices in connection with the marketing, advertising, and sales of the Product;
  - d. Whether Defendant violated other consumer protection statutes, false advertising statutes, or state deceptive business practices statutes;
  - e. Whether Defendant's conduct violates public policy; whether Defendant's conduct violates state and federal food statutes or regulations; whether the Product is misbranded;
  - f. The proper amount of restitution, damages, and punitive damages;
  - g. The proper injunctive relief, including a corrective advertising campaign; and
  - h. The proper amount of attorneys' fees.
- 85. These common questions of law and fact predominate over questions that affect only individual Class Members.
- 86. Plaintiffs' claims are typical of Class Members' claims because they are based on the same underlying facts, events, and circumstances relating to Defendant's conduct. Specifically, all Class Members, including Plaintiffs, were subjected to the same misleading and deceptive conduct when they purchased the Product, and suffered economic injury because the Product was and still is

misrepresented. Absent Defendant's business practice of deceptively and unlawfully labeling the Product, Plaintiffs and Class Members would not have purchased the Product.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

- 87. Plaintiffs will fairly and adequately represent and protect the interests of the Classes, have no interests incompatible with the interests of the Classes, and have retained counsel with substantial experience in handling complex class action litigation in general and scientific claims specifically, including for dietary supplements. Plaintiffs and their counsel are committed to vigorously prosecuting this action on behalf of the Classes and have the financial resources to do so.
- 88. Plaintiffs and the members of the Classes suffered, and will continue to suffer harm as a result of the Defendant's unlawful and wrongful conduct. A class action is superior to other available methods for the fair and efficient adjudication of the present controversy. Individual joinder of all members of the Classes is impracticable. Even if individual Class members had the resources to pursue individual litigation, it would be unduly burdensome to the courts in which the individual litigation would proceed. Individual litigation magnifies the delay and expense to all parties in the court system of resolving the controversies engendered by Defendant's common course of conduct. The class action device allows a single court to provide the benefits of unitary adjudication, judicial economy, and the fair and efficient handling of all Class members' claims in a single forum. The conduct of this action as a class action conserves the resources of the parties and of the judicial system and protects the rights of the class members. Furthermore, for many, if not most, a class action is the only feasible mechanism that allows an opportunity for legal redress and justice.
- 89. Adjudication of individual Class members' claims with respect to Defendant would, as a practical matter, be dispositive of the interests of other members not parties to the adjudication, and could substantially impair or impede the ability of other class members to protect their interests.

- 90. Defendant has acted on grounds applicable to the Class, thereby making appropriate final public injunctive and declaratory relief concerning the Class as a whole.
- 91. As a result of the foregoing, class treatment is appropriate under Fed. R. Civ. P. 23(b)(2) and 23(b)(3).

#### **CAUSES OF ACTION**

#### FIRST CAUSE OF ACTION

Violations of the Unfair Competition Law,

Cal. Bus. & Prof. Code §§ 17200 et seq.

(by the Nationwide Class and California Class)

- 92. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if set forth in full herein.
- 93. California's Unfair Competition Law, Business and Professions Code §17200 (the "UCL") prohibits any "unfair, deceptive, untrue or misleading advertising." For the reasons discussed above, Defendant has engaged in unfair, deceptive, untrue and misleading advertising, and continues to engage in such business conduct, in violation of the UCL.
- 94. California's Unfair Competition Law ("UCL"), Cal. Bus. & Prof. Code §§ 17200, *et seq.*, proscribes acts of unfair competition, including "any unlawful, unfair or fraudulent business act or practice and unfair, deceptive, untrue or misleading advertising."

#### **Fraudulent**

- 95. A statement or practice is "fraudulent" under the UCL if it is likely to mislead or deceive the public, applying an objective reasonable consumer test.
- 96. As set forth herein, Defendant's claims relating to the Product are likely to mislead reasonable consumers to believe the Product can provide weight-loss benefits, when it cannot.

- 97. Defendant's conduct caused and continues to cause substantial injury to Plaintiffs and the other Class members. Plaintiffs have suffered injury in fact as a result of Defendant's unfair conduct. Defendant has thus engaged in unlawful, unfair and fraudulent business acts and practices and false advertising, entitling Plaintiffs and the Class to public injunctive relief against Defendant, as set forth in the Prayer for Relief.
- 98. Pursuant to Business and Professions Code §17203, Plaintiffs and the Class seek an order requiring Defendant to immediately cease such acts of unlawful, unfair and fraudulent business practices and requiring Defendant to engage in a corrective advertising campaign.
- 99. Plaintiffs also seek an order for the disgorgement and restitution of all monies from the sale of the Products the Class Members purchased, which was unjustly acquired through acts of unlawful, unfair, and/or fraudulent competition and attorneys' fees and costs.

#### **Unlawful**

- 100. The acts alleged herein are "unlawful" under the UCL in that they violate at least the following laws:
  - a. By knowingly and intentionally concealing from Plaintiffs and the other Class members that the Product cannot provide the advertised weight-loss benefits while obtaining money from Plaintiffs and the Classes;
  - b. By misrepresenting the nature of the Product and the Product's effectiveness at providing the weight-loss benefits;
  - c. By engaging in the conduct giving rise to the claims asserted in this complaint;
  - d. By violating California Civil Code §§ 1709-1711 by making affirmative misrepresentations about the Product;

- 1 2
- 3
- 5
- 7
- 9

- 10
- 11
- 1213
- 14
- 15
- 16
- 1718
- 19
- 2021
- 2223
- 24
- 2526
- 2728

- e. By violating California Civil Code §§ 1709-1711 by suppressing material information about the Product;
- f. By violating the California Commercial Code for breaches of express and implied warranties.
- g. By violating Cal. Bus. & Prof. Code§ 12606.2 and 21 C.F.R. § 100.100;
- h. By violating the False Advertising Law, Cal. Bus. & Prof. Code §§ 17500 *et seq.*;
- i. By violating the Consumers Legal Remedies Act, Cal. Civ. Code §§ 1750 et seq.;
- j. By violating the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.§§ 301 et seq.; and
- k. By violating the California Sherman Food, Drug, and Cosmetic Law, Cal. Health & Safety Code §§ 110100 *et seq*.
- 101. Such conduct is ongoing and continues to this date.
- 102. Plaintiffs and the Class reserve the right to allege other violations of law, which constitute other unlawful business acts or practices.
- 103. Defendant's acts, omissions, misrepresentations, practices and nondisclosures as alleged herein also constitute "unfair" business acts and practices within the meaning of the UCL in that its conduct is substantially injurious to consumers, offends public policy, and is immoral, unethical, oppressive, and unscrupulous as the gravity of the conduct outweighs any alleged benefits attributable to such conduct. In the alternative, Defendant's business conduct as described herein violates relevant laws designed to protect consumers and business from unfair competition in the marketplace. Such conduct is ongoing and continues to date.
- 104. Defendant's conduct with respect to the labeling, advertising, and sale of the Product was and is also unfair because it violates public policy as declared by

specific constitutional, statutory or regulatory provisions, including but not limited to the Consumers Legal Remedies Act, the False Advertising Law, portions of the Federal Food, Drug, and Cosmetic Act, and portions of the California Sherman Food, Drug, and Cosmetic Law.

- 105. Defendant's conduct with respect to the labeling, advertising, and sale of the Product was and is also unfair because the consumer injury was substantial, not outweighed by benefits to consumers or competition, and not one consumers themselves could reasonably have avoided.
- 106. Defendant profited from its sale of the falsely, deceptively, and unlawfully advertised and packaged Product to unwary consumers.
- 107. Plaintiffs and Class Members are likely to continue to be damaged by Defendant's deceptive trade practices, because Defendant continues to disseminate misleading information on the Product's packaging. Thus, public injunctive relief enjoining Defendant's deceptive practices is proper.
- 108. There were reasonably available alternatives to further Defendant's legitimate business interests, other than the conduct described herein.

#### **SECOND CAUSE OF ACTION**

Violations of the False Advertising Law,

Cal. Bus. & Prof. Code §§ 17500 et seq.

(by the Nationwide Class and California Class)

- 109. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if set forth in full herein.
- 110. The FAL provides that "[i]t is unlawful for any person, firm, corporation or association, or any employee thereof with intent directly or indirectly to dispose of real or personal property or to perform services" to disseminate any statement "which is untrue or misleading, and which is known, or which by the exercise of reasonable care should be known, to be untrue or misleading." Cal. Bus. & Prof. Code § 17500.

- 111. It is also unlawful under the FAL to disseminate statements concerning property or services that are "untrue or misleading, and which is known, or which by the exercise of reasonable care should be known, to be untrue or misleading." *Id*.
- 112. As alleged herein, the advertisements, labeling, policies, acts, and practices of Defendant relating to the Product misled consumers acting reasonably as to the effectiveness and weight-loss properties of the Product.
- 113. Plaintiffs have standing to pursue this claim as Plaintiffs have suffered injury in fact as a result of Defendant's actions as set forth herein. Specifically, prior to the filing of this action, Plaintiffs purchased the Product in reliance on Defendant's false and misleading labeling claims that the Product, among other things, aids in weight management and provides appetite control.
- 114. Defendant's business practices as alleged herein constitute deceptive, untrue, and misleading advertising pursuant to the FAL because Defendant has advertised the Product in a manner that is untrue and misleading, which Defendant knew or reasonably should have known, and omitted material information from its advertising.
- 115. Defendant profited from its sale of the falsely and deceptively advertised Product to unwary consumers.
- 116. As a result, Plaintiffs, the Class, and the general public are entitled to public injunctive and equitable relief, restitution, and an order for the disgorgement of the funds by which Defendant was unjustly enriched.
- 117. Pursuant to Cal. Bus. & Prof. Code § 17535, Plaintiffs, on behalf of themselves and the Class, seek an order enjoining Defendant from continuing to engage in deceptive business practices, false advertising, and any other act prohibited by law, including those set forth in this Complaint.

#### THIRD CAUSE OF ACTION

Violations of the Consumer Legal Remedies Act, Cal. Civ. Code §§ 1750 et seq.

#### (on behalf of the Nationwide Class and California Class)

118. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if set forth in full herein.

- 119. The CLRA prohibits deceptive practices in connection with the conduct of a business that provides goods, property, or services primarily for personal, family, or household purposes.
- 120. Defendant's false and misleading labeling and other policies, acts, and practices were designed to, and did, induce the purchase and use of the Product for personal, family, or household purposes by Plaintiffs and Class Members, and violated and continue to violate the following sections of the CLRA:
  - a. § 1770(a)(5): representing that goods have characteristics, uses, or benefits which they do not have;
  - b. § 1770(a)(7): representing that goods are of a particular standard, quality, or grade if they are of another;
  - c. § 1770(a)(9): advertising goods with intent not to sell them as advertised; and
  - d. § 1770(a)(16): representing the subject of a transaction has been supplied in accordance with a previous representation when it has not.
- 121. Defendant profited from the sale of the falsely, deceptively, and unlawfully advertised Product to unwary consumers.
- 122. Defendant's wrongful business practices constituted, and constitute, a continuing course of conduct in violation of the CLRA.
- 123. On or about February 28, 2019, prior to filing this action, Plaintiff Capaci sent a CLRA notice letter to Defendant which complies with California Civil Code 1782(a). Plaintiff Capaci sent Sports Research Corporation, individually and on behalf of the proposed Class, a letter via Certified Mail, advising Defendant that it is in violation of the CLRA and demanding that it cease and desist from such

4

10

12

13 14

16

17

15

18 19

20 21

22 23

25

26

24

27

28

violations and make full restitution by refunding the monies received therefrom. A copy of Plaintiff Capaci's CLRA letter is attached hereto as Exhibit 1. As of the date of this filing, Defendant has failed to take corrective action.

124. Wherefore, Plaintiffs seek public injunctive relief, actual damages, restitution, and attorneys' fees and costs for Defendant's violations of the CLRA.

#### FOURTH CAUSE OF ACTION

## **Breach of Express Warranties**,

Cal. Com. Code § 2313(1)

(by the Nationwide Class and California Class)

- 125. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if set forth in full herein.
- 126. Through the Product's label and advertising, Defendant made affirmations of fact or promises, or description of goods, described above, which were "part of the basis of the bargain," in that Plaintiffs and the Class purchased the Product in reasonable reliance on those statements. Cal. Com. Code § 2313(1).
- 127. The foregoing representations were material and were a substantial factor in causing the harm suffered by Plaintiffs and the Class because they concerned alleged efficacy of the Product regarding the ability to aid with weight management and appetite control.
- These representations had an influence on consumers' decisions in 128. purchasing the Product.
- 129. Defendant made the above representations to induce Plaintiffs and the members of Class to purchase the Product. Plaintiffs and the Class members relied on the representations when purchasing Defendant's product.
- 130. Defendant breached the express warranties by selling a Product that does not and cannot provide the promised benefits.
- That breach actually and proximately caused injury in the form of the lost purchase price that Plaintiffs and Class members paid for the Product.

#### **FIFTH CAUSE OF ACTION**

#### **Breach of Implied Warranties,**

#### **Cal. Com. Code § 2314**

(by the Nationwide Class and California Class)

- 132. Plaintiffs reallege and incorporate the allegations elsewhere in the Complaint as if set forth in full herein.
- 133. Defendant, through its acts and omissions set forth herein, in the sale, marketing, and promotion of the Product, made representations to Plaintiffs and the Class that, among other things, the Product would aid in weight management and appetite control.
- 134. Plaintiffs and the Class bought the Product manufactured, advertised, and sold by Defendant, as described herein.
- 135. Defendant is a merchant with respect to the goods of this kind which were sold to Plaintiffs and the Class, and there was, in the sale to Plaintiffs and other consumers, an implied warranty that those goods were merchantable.
- 136. However, Defendant breached that implied warranty in that the Product does not aid in weight management and appetite control.
- 137. As an actual and proximate result of Defendant's conduct, Plaintiffs and the Class did not receive goods as impliedly warranted by Defendant to be merchantable in that it did not conform to promises and affirmations made on the container or label of the goods nor is it fit for its ordinary purpose, aiding in weight management and appetite control.
- 138. Plaintiffs and Class have sustained damages as a proximate result of the foregoing breach of implied warranty in the amount of the Product's purchase price.

#### **SIXTH CAUSE OF ACTION**

**Claim for Negligent Misrepresentation** 

(on behalf of all Classes)

- 139. Plaintiffs and the Class Members re-allege and incorporate by reference each and every allegation set forth above, and further allege as follows:
- 140. Defendant had a duty to disclose to Plaintiffs and Class Members correct information as to the quality and characteristics of the Product because Defendant was in a superior position than Plaintiffs and Class Members such that reliance by Plaintiffs and Class Members were justified. Defendant possessed the skills and expertise to know the type of information that would influence a consumer's purchasing decision.
- 141. During the applicable Class period, Defendant negligently or carelessly misrepresented, omitted, and concealed from consumers material facts regarding the quality and characteristics of the Product, including the alleged weight-loss benefits.
- 142. Defendant made such false and misleading statements and omissions with the intent to induce Plaintiffs and Class Members to purchase the Product.
- 143. Defendant was careless in ascertaining the truth of its representations in that it knew or should have known that Plaintiffs and Class Members would not realize the alleged benefits represented by Defendant.
- 144. Plaintiffs and the Class Members were unaware of the falsity in Defendant's misrepresentations and omissions and, as a result, justifiably relied on them when making the decision to purchase the Product.
- 145. Plaintiffs and the Class Members would not have purchased the Product or paid as much for the Product if the true facts had been known.

#### SEVENTH CAUSE OF ACTION

**Violations of New Jersey's Consumer Fraud Act** 

N.J.S.A. § 56:8-1, et seq.

(by the New Jersey Class)

146. Plaintiffs and the Class members incorporate by reference and re-allege each and every allegation set forth above as though fully set forth herein.

- 147. Plaintiffs bring this claim on behalf of each member of the New Jersey Class.
- 148. Defendant, by selling, distributing, designing, packaging and marketing the Product, as set forth above, engaged in deceptive practices and acts in violation of the New Jersey Consumer Fraud Act, N.J.S.A. § 56:8-2.
- 149. "To violate the Act, a person must commit an 'unlawful practice' as defined in the legislation. Unlawful practices fall into three general categories: affirmative acts, knowing omissions, and regulation violations." Cox v. Sears Roebuck & Co., 138 N.J. 2, 17 (1994) ("The capacity to mislead is the prime ingredient of all types of consumer fraud.").
- 150. Defendant used unconscionable commercial practices, deception, false pretense, false promises, misrepresentations, or the knowing, concealment, suppression, or omission of material facts with intent that others, including Plaintiffs and the New Jersey class members, would rely upon such concealment, suppression or omission, in connection with the sale and advertisement of the Product, which is "merchandise" under the New Jersey Consumer Fraud Act.
- 151. Defendant's misrepresentations and false, deceptive, and misleading statements with respect to the Product, as described above, constitute deceptive acts or practices.
- 152. Defendant's representations and warranties constitute "affirmative acts" under the NJCFA.
- 153. Defendant's failures to disclosure material facts about the Product constitute "knowing omissions."
- 154. Defendant engaged in an unconscionable commercial practice because Defendant knew the contents and ingredients in the Product, and therefore Defendant's sale and labeling of the Product demonstrates a lack of good faith, and disregard for honesty and fair dealing.

- 155. Defendant engaged in acts of omission, including, but not limited to knowing concealment, suppression and omission of material facts. Defendant knew the contents and ingredients in the Product and knew that Product was nothing more than a placebo. Nonetheless, Defendant knowingly concealed, suppressed, and/or omitted the true capabilities of the Product, given consumers' desire for breakthrough weight-loss supplements. Defendant intended that consumers rely upon its misleading representations in purchasing the Product.
- 156. Plaintiffs and the Class suffered an ascertainable loss caused by Defendant's misrepresentations, unconscionable commercial practices, and knowing omissions because (a) they would not have purchased Product on the same terms if the true facts concerning its actual capabilities had been known; and (b) they paid a price premium due to the misrepresentation of the Product.
- 157. Based on the foregoing, Plaintiffs and the New Jersey class members are entitled to all remedies available pursuant to the New Jersey Consumer Fraud Act, including, but not limited to actual damages, treble damages, disgorgement of Defendant's profits derived from its unlawful activities, public injunctive relief, attorneys' fees and other reasonable costs.

#### EIGHTH CAUSE OF ACTION

# VIOLATIONS OF THE NEW JERSEY TRUTH-IN-CONSUMER CONTRACT, WARRANTY AND NOTICE ACT "TCCWNA,"

New Jersey Stat. §§ 56:12-14 to 56:12-18 (by the New Jersey Class)

- 158. Plaintiffs and the Class members incorporate by reference and re-allege each and every allegation set forth above as though fully set forth herein.
  - 159. New Jersey Stat. §§ 56:12-15 (the "TCCWNA") provides:
- 160. No seller . . . shall in the course of his business offer to any consumer or prospective consumer or enter into any written consumer contract or give or display any written consumer warranty, notice or sign . . . which includes any

- 161. The labels and marketing materials for the Product are written consumer warranties, notices, and/or signs that are offered, given, and/or displayed to consumers and prospective consumers subject to the TCCWNA.
- 162. Plaintiffs and the New Jersey Class are "consumer[s] or prospective consumer[s]" within the meaning of N.J.S.A. § 56:12-15.
  - 163. Defendant is a "seller" within the meaning of N.J.S.A. § 56:12-15.
- 164. The right of consumers to truthful and accurate statements on the labels and marketing materials for the Product, as well as the right to avoid deception caused by false and misleading statements on such labels and marketing materials, are "clearly established legal rights" under N.J.S.A. § 56:8-2.
- 165. The responsibility of a seller to refrain from the employment of any unconscionable commercial practice, deception, fraud, false pretense, and/or misrepresentation, and to refrain from the knowing concealment, suppression, and/or omission of any material fact with intent that others rely upon such concealment, suppression, and/or omission in connection with the sale of merchandise, and to refrain from selling products with labels that make false statements about the products, is clearly established under N.J.S.A. § 56:8-2.
- 166. Defendant violated the TCCWNA by stating that the Product could provide weight management support and appetite control, when in fact, the Product is no better than a placebo.
- 167. Pursuant to N.J.S.A. § 56:12-17, Defendant is liable to Plaintiffs and the New Jersey Class for civil penalties or for actual damages, or both, at the election of the consumer. In addition, Plaintiffs and the New Jersey Class are entitled to

reimbursement for all reasonable attorneys' fees and court costs incurred as a result of bringing this action.

3

### VI. PRAYER FOR RELIEF

45

168. Wherefore, Plaintiffs, on behalf of themselves, all others similarly situated and the general public, pray for judgment against Defendant as to each and every cause of action, including:

6 7

a. An order certifying this action as a class action pursuant to Federal Rules of Civil Procedure 23(b)(1), 23(b)(2), and/or 23(b)(3);

8

b. An order maintaining this action as a class action and/or an order maintaining a particular issue class action pursuant to Federal Rule of Civil Procedure 23(c)(4);

1112

10

c. An order requiring Defendant to bear the costs of class notice;

13

14

d. An order appointing Plaintiffs Frank Capaci and Cynthia Ford as the class representatives and the Law Offices of Ronald A. Marron as Class Counsel;

1516

e. An Order compelling Defendant to conduct a corrective advertising campaign;

1718

f. An Order compelling Defendant to destroy all misleading and deceptive advertising materials and product labels, and to recall all offending Products:

19 20

g. An Order awarding disgorgement of Defendant's profits that were obtained from its ill-gotten gains in connection with its sales of the

2223

21

h. An Order awarding restitution in the amount of the purchase price paid by the class members for the Product;

24

25

i. An award for punitive damages;

2627

j. An award awarding attorneys' fees and costs; and

Product to Plaintiffs and the class members:

28

k. An Order providing for all other such further relief as may be just and

1 proper. 2 **JURY DEMAND** Plaintiffs hereby demand a trial by jury on all issues so triable. 3 4 5 Dated: April 6, 2020 Respectfully Submitted, 6 7 /s/ Ronald A. Marron 8 Ronald A. Marron 9 10 LAW OFFICES OF RONALD A. MARRON RONALD A. MARRON 11 ron@consumersadvocates.com 12 MICHAEL T. HOUCHIN mike@consumersadvocates.com 13 LILACH HALPERIN 14 lilach@consumersadvocates.com 651 Arroyo Drive 15 San Diego, California 92103 16 Telephone: (619) 696-9006 17 Facsimile: (619) 564-6665 Counsel for Plaintiffs and the Proposed Class 18 19 20 21 22 23 24 25 26 27 28